Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib Adjuvant Therapy in EGFR-mutated Stage IIA-IIIA Lung Adenocarcinoma
NCT02044328Phase 2Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Jan 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Jan 2014; status: completed.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02044328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044328.